Clinical Trial Update: Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating irinotecan plus raltitrexed as second-line therapy for advanced colorectal cancer. Sponsored by China Medical University, China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Raltitrexed (Raltitrexed)

Snippet

Sponsor: China Medical University, China | Conditions: ColoRectal Cancer | Phase 2 | Status: UNKNOWN